Case study on the utility of hepatic global gene expression profiling in the risk assessment of the carcinogen furan

Toxicology and Applied Pharmacology

Volumn 274, Issue 1, 2014, Pages 63-77

  Jackson, Anna Francina ^a,b   Williams, Andrew ^a   Recio, Leslie ^c   Waters, Michael D ^c   Lambert, Iain B ^b   Yauk, Carole L ^a  

^a HEALTH CANADA   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c ILS Inc   (United States)

Author keywords

Furan; Gene expression; Indirect acting genotoxic carcinogen; Non genotoxic carcinogen; Risk assessment; Toxicogenomics

Indexed keywords

CARCINOGEN; CYTOCHROME P450 2E1; DEATH RECEPTOR 5; FURAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CHRONIC INFLAMMATION; CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; LIVER REGENERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; RISK ASSESSMENT; XENOBIOTIC METABOLISM;

EID: 84889602466     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.10.019     Document Type: Article

References (111)

1. Alcorn J.A., Feitelberg S.P., Brenner D.A. Transient induction of c-Jun during hepatic regeneration. Hepatology 1990, 11:909-915.
2. Ameri K., Harris A.L. Activating transcription factor 4. Int. J. Biochem. Cell Biol. 2008, 40:14-21.
3. Amir M., Liu K., Zhao E., Czaja M.J. Distinct functions of JNK and c-Jun in oxidant-induced hepatocyte death. J. Cell. Biochem. 2012, 113:3254-3265.
4. Arnér E.S.J., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267:6102-6109.
5. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
6. Becker R.A., Chambers J.M., Wilks A.R. The New S Language 1998, Chapman and Hall/CRC.
7. Behrens A., Sibilia M., David J., Möhle-Steinlein U., Tronche F., Schütz G., Wagner E.F. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-Jun in the liver. EMBO J. 2002, 21:1782-1790.
8. Benford D., Bolger P.M., Carthew P., Coulet M., DiNovi M., Leblanc J.C., Renwick A.G., Setzer W., Schlatter J., Smith B., Slob W., Williams G., Wildemann T. Application of the Margin of Exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem. Toxicol. 2010, 48(Suppl. 1):S2-S24.
9. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B (Methodological) 1995, 57:289-300.
10. Berasain C., Castillo J., Perugorria M.J., Latasa M.U., Prieto J., Avila M.A. Inflammation and liver cancer: new molecular links. Ann. N. Y. Acad. Sci. 2009, 1155:206-221.
11. Black M.B., Budinsky R.A., Dombkowski A., Cukovic D., LeCluyse E.L., Ferguson S.S., Thomas R.S., Rowlands J.C. Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Sci. 2012, 127:199-215.
12. Bolstad B.M., Irizarry R.A., Åstrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
13. Carfagna M.A., Held S.D., Kedderis G.L. Furan-induced cytolethality in isolated rat hepatocytes: correspondence with in vivo dosimetry. Toxicol. Appl. Pharmacol. 1993, 123:265-273.
14. Carthew P., DiNovi M., Woodrow Setzer R. Application of the Margin of Exposure (MOE) approach to substances in food that are genotoxic and carcinogenic: example: CAS no: 105650-23-5 PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine). Food Chem. Toxicol. 2010, 48(Suppl. 1):S98-S105.
15. Chaisson M.L., Brooling J.T., Ladiges W., Tsai S., Fausto N. Hepatocyte-specific inhibition of NF-κB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J. Clin. Invest. 2002, 110:193-202.
16. Chen Q., Galleano M., Cederbaum A.I. Cytotoxicity and apoptosis produced by arachidonic acid in HepG2 cells overexpressing human cytochrome P-4502E1. Alcohol. Clin. Exp. Res. 1998, 22:782-784.
17. Chu W.M. Tumor necrosis factor. Cancer Lett. 2013, 328:222-225.
18. Cordelli E., Leopardi P., Villani P., Marcon F., Macri C., Caiola S., Siniscalchi E., Conti L., Eleuteri P., Malchiodi-Albedi F., Crebelli R. Toxic and genotoxic effects of oral administration of furan in mouse liver. Mutagenesis 2010, 25:305-314.
19. Cressman D.E., Greenbaum L.E., Haber B.A., Taub R. Rapid activation of post-hepatectomy factor/nuclear factor κB in hepatocytes, a primary response in the regenerating liver. J. Biol. Chem. 1994, 269:30429-30435.
20. Cui X., Hwang J.T., Qiu J., Blades N.J., Churchill G.A. Improved statistical tests for differential gene expression by shrinking variance components estimates. Biostatistics 2005, 6:59-75.
21. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
22. Davis J.A., Gift J.S., Zhao Q.J. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1. Toxicol. Appl. Pharmacol. 2011, 254:181-191.
23. Denicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S., Scrimieri F., Winter J.M., Hruban R.H., Iacobuzio-Donahue C., Kern S.E., Blair I.A., Tuveson D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-110.
24. DiDonato J.A., Mercurio F., Karin M. NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 2012, 246:379-400.
25. Diehl A.M., Yin M., Fleckenstein J., Yang S.Q., Lin H.Z., Brenner D.A., Westwick J., Bagby G., Nelson S. Tumor necrosis factor-alpha induces c-Jun during the regenerative response to liver injury. Am. J. Physiol. 1994, 267:G552-G561.
26. Ding W., Petibone D.M., Latendresse J.R., Pearce M.G., Muskhelishvili L., White G.A., Chang C., Mittelstaedt R.A., Shaddock J.G., McDaniel L.P., Doerge D.R., Morris S.M., Bishop M.E., Manjanatha M.G., Aidoo A., Heflich R.H. In vivo genotoxicity of furan in F344 rats at cancer bioassay doses. Toxicol. Appl. Pharmacol. 2012, 261:164-171.
27. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 1955, 50. (1096-1096-1121).
28. Durling L.J., Svensson K., Abramsson-Zetterberg L. Furan is not genotoxic in the micronucleus assay in vivo or in vitro. Toxicol. Lett. 2007, 169:43-50.
29. Eferl R., Ricci R., Kenner L., Zenz R., David J., Rath M., Wagner E.F. Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53. Cell 2003, 112:181-192.
30. Eferl R., Sibilia M., Hilberg F., Fuchsbichler A., Kufferath I., Guertl B., Zenz R., Wagner E.F., Zatloukal K. Functions of c-Jun in liver and heart development. J. Cell Biol. 1999, 145:1049-1061.
31. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 2003, 3:859-868.
32. EFSA EFSA - Scientific Opinion of the Scientific Committee: Opinion of the Scientific Committee on a Request from EFSA Related to a Harmonised Approach for Risk Assessment of Substances Which Are Both Genotoxic and Carcinogenic 2005, (2013).
33. FitzGerald M.J., Webber E.M., Donovan J.R., Fausto N. Rapid DNA binding by nuclear factor κB in hepatocytes at the start of liver regeneration. Cell Growth Differ. 1995, 6:417-427.
34. Fransson-Steen R., Goldsworthy T.L., Kedderis G.L., Maronpot R.R. Furan-induced liver cell proliferation and apoptosis in female B6C3F1 mice. Toxicology 1997, 118:195-204.
35. Gan L., Guo K., Li Y., Kang X., Sun L., Shu H., Liu Y. Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol. Rep. 2010, 23:1037-1043.
36. Gates L.A., Lu D., Peterson L.A. Trapping of cis-2-butene-1,4-dial to measure furan metabolism in human liver microsomes by cytochrome P450 enzymes. Drug Metab. Dispos. 2012, 40:596-601.
37. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. Affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.
38. Gill S., Bondy G., Lefebvre D.E., Becalski A., Kavanagh M., Hou Y., Turcotte A.M., Barker M., Weld M., Vavasour E., Cooke G.M. Subchronic oral toxicity study of furan in Fischer-344 rats. Toxicol. Pathol. 2010, 38:619-630.
39. Gill S., Kavanagh M., Barker M., Weld M., Vavasour E., Hou Y., Cooke G.M. Subchronic oral toxicity study of furan in B6C3F1 mice. Toxicol. Pathol. 2011, 39:787-794.
40. Gonzalez F.J. The 2006 Bernard B. Brodie award lecture. Cyp2e1. Drug Metab. Dispos. 2007, 35:1-8.
41. Gonzalez F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2005, 569:101-110.
42. Hai T., Wolfgang C.D., Marsee D.K., Allen A.E., Sivaprasad U. ATF3 and stress responses. Gene Expr. 1999, 7:321-335.
43. Haseman J.K., Hailey J.R., Morris R.W. Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: a National Toxicology Program update. Toxicol. Pathol. 1998, 26:428. 10.1177/019262339802600318.
44. Hayes J.D., McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol. Cell 2006, 21:732-734.
45. Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci. 2004, 117:5965-5973.
46. Hickling K.C., Hitchcock J.M., Oreffo V., Mally A., Hammond T.G., Evans J.G., Chipman J.K. Evidence of oxidative stress and associated DNA damage, increased proliferative drive, and altered gene expression in rat liver produced by the cholangiocarcinogenic agent furan. Toxicol. Pathol. 2010, 38:230-243.
47. Hilberg F., Aguzzi A., Howells N., Wagner E.F. c-Jun is essential for normal mouse development and hepatogenesis. Nature 1993, 365:179-181.
48. Hothorn T., Bretz F., Westfall P. Simultaneous inference in general parametric models. Biom. J. 2008, 50:346-363.
49. Hsieh S.Y., Huang S.F., Yu M.C., Yeh T.S., Chen T.C., Lin Y.J., Chang C.J., Sung C.M., Lee Y.L., Hsu C.Y. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol. Carcinog. 2010, 49:476-487.
50. IARC Dry cleaning, some chlorinated solvents, and other industrial chemicals 1995, 3407(63):3194.
51. IRIS Furan (CASRN 110-00-9) (2013). http://www.epa.gov/iris/subst/0056.htm.
52. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
53. Jaeschke H., Gores G.J., Cederbaum A.I., Hinson J.A., Pessayre D., Lemasters J.J. Mechanisms of hepatotoxicity. Toxicol. Sci. 2002, 65:166-176.
54. Jochum W., Passegué E., Wagner E.F. AP-1 in mouse development and tumorigenesis. Oncogene 2001, 20:2401-2412.
55. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 2009, 1:a000141.
56. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
57. Karin M., Shaulian E. AP-1: linking hydrogen peroxide and oxidative stress to the control of cell proliferation and death. IUBMB Life 2001, 52:17-24.
58. Kedderis G.L., Held S.D. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol. Appl. Pharmacol. 1996, 140:124-130.
59. Kellert M., Brink A., Richter I., Schlatter J., Lutz W.K. Tests for genotoxicity and mutagenicity of furan and its metabolite cis-2-butene-1,4-dial in L5178Y tk+/- mouse lymphoma cells. Mutat. Res. 2008, 657:127-132.
60. Kupershmidt I., Su Q.J., Grewal A., Sundaresh S., Halperin I., Flynn J., Shekar M., Wang H., Park J., Cui W., Wall G.D., Wisotzkey R., Alag S., Akhtari S., Ronaghi M. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 2010, 5. 10.1371/journal.pone.0013066.
61. Larson J.L., Wolf D.C., Butterworth B.E. Induced cytolethality and regenerative cell proliferation in the livers and kidneys of male B6C3F1 mice given chloroform by gavage. Fundam. Appl. Toxicol. 1994, 23:537-543.
62. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
63. Leopardi P., Cordelli E., Villani P., Cremona T.P., Conti L., De Luca G., Crebelli R. Assessment of in vivo genotoxicity of the rodent carcinogen furan: evaluation of DNA damage and induction of micronuclei in mouse splenocytes. Mutagenesis 2010, 25:57-62.
64. Li Q., Van Antwerp D., Mercurio F., Lee K.F., Verma I.M. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999, 284:321-325.
65. Ligges U., Mächler M. Scatterplot3d - an R package for visualizing multivariate data. J. Stat. Softw. 2003, 8:1-20.
66. Liu H., Jones B.E., Bradham C., Czaja M.J. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alpha. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G257-G266.
67. Lu Y., Cederbaum A.I. CYP2E1 potentiation of LPS and TNFalpha-induced hepatotoxicity by mechanisms involving enhanced oxidative and nitrosative stress, activation of MAP kinases, and mitochondrial dysfunction. Genes Nutr. 2010, 5:149-167.
68. Lu Y., Cederbaum A.I. CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol. Med. 2008, 44:723-738.
69. Luedde T., Schwabe R.F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:108-118.
70. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
71. Maga J.A., Katz I. Furans in foods. Crit. Rev. Food Sci. Nutr. 1979, 11:355-400.
72. Manibusan M.K., Odin M., Eastmond D.A. Postulated carbon tetrachloride mode of action: a review. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2007, 25:185-209.
73. Mardia K.V., Kent J.T., Bibby J.M. Multivariate Analysis 1979, Academic Press, London.
74. McDaniel L.P., Ding W., Dobrovolsky V.N.G. Mittelstaedt R.A., Doerge D.R., Heflich R.H. Genotoxicity of furan in Big Blue rats. Mutat. Res. 2012, 742:72-78.
75. Meloche S., Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26:3227-3239.
76. Min L., He B., Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin. Cancer Biol. 2011, 21:10-20.
77. Min L., Ji Y., Bakiri L., Qiu Z., Cen J., Chen X., Chen L., Scheuch H., Zheng H., Qin L., Zatloukal K., Hui L., Wagner E.F. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 2012, 14:1203-1211.
78. Moro S., Chipman J.K., Wegener J.W., Hamberger C., Dekant W., Mally A. Furan in Heat-treated Foods: Formation, Exposure, Toxicity, and Aspects of Risk Assessment 2012, Molecular Nutrition & Food Research.
79. Moser G.J., Foley J., Burnett M., Goldsworthy T.L., Maronpot R. Furan-induced dose-response relationships for liver cytotoxicity, cell proliferation, and tumorigenicity (furan-induced liver tumorigenicity). Exp. Toxicol. Pathol. 2009, 61:101-111.
80. Nakagawa H., Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Pathol. Res. Int. 2012, 2012:172894.
81. Nakano H., Nakajima A., Sakon-Komazawa S., Piao J.H., Xue X., Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 2006, 13:730-737.
82. Neuwirth C., Mosesso P., Pepe G., Fiore M., Malfatti M., Turteltaub K., Dekant W., Mally A. Furan Carcinogenicity: DNA Binding and Genotoxicity of Furan in Rats In Vivo 2012, Molecular Nutrition & Food Research.
83. NTP NTP Technical Report on the Toxicology and Carcinogenesis Studies of Furan in F344/N Rats and B6C3F1 Mice (Gavage Studies) 1993, 402.
84. Okazaki T., Himi T., Peterson C., Mori N. Induction of stathmin mRNA during liver regeneration. FEBS Lett. 1993, 336:8-12.
85. Papa S., Zazzeroni F., Pham C.G., Bubici C., Franzoso G. Linking JNK signaling to NF-kappaB: a key to survival. J. Cell Sci. 2004, 117:5197-5208.
86. Pastorino J.G., Hoek J.B. Ethanol potentiates tumor necrosis factor-alpha cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition. Hepatology 2000, 31:1141-1152.
87. Patterson K.I., Brummer T., O'Brien P.M., Daly R.J. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 2009, 418:475-489.
88. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
89. R-Development-Core-Team R: A Language and Environment for Statistical Computing 2010, R Foundation for Statistical Computing, Vienna, Austria, (http://www.lsw.uni-heidelberg.de/users/christlieb/teaching/UKStaSS10/R-refman.pdf).
90. Rowlands D.C., Harrison R.F., Jones N.A., Williams A., Hubscher S.G., Brown G. Stathmin is expressed by the proliferating hepatocytes during liver regeneration. J. Clin. Pathol. Clin. Mol. Pathol. 1995, 48:M88-M92.
91. Rudolph D., Yeh W., Wakeham A., Rudolph B., Nallainathan D., Potter J., Elia A.J., Mak T.W. Severe liver degeneration and lack of NF-κB activation in NEMO/IKK γ-deficient mice. Genes Dev. 2000, 14:854-862.
92. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17:2596-2606.
93. Schrum L.W., Black D., Iimuro Y., Rippe R.A., Brenner D.A., Behrns K.E. c-Jun does not mediate hepatocyte apoptosis following NFκB inhibition and partial hepatectomy. J. Surg. Res. 2000, 88:142-149.
94. Seki E., Brenner D.A., Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012, 143:307-320.
95. Singh R., Czaja M.J. Regulation of hepatocyte apoptosis by oxidative stress. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S45-S48.
96. Singh R., Wang Y., Schattenberg J.M., Xiang Y., Czaja M.J. Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G907-G917.
97. Templin M.V., Jamison K.C., Sprankle C.S., Wolf D.C., Wong B.A., Butterworth B.E. Chloroform-induced cytotoxicity and regenerative cell proliferation in the kidneys and liver of BDF1 mice. Cancer Lett. 1996, 108:225-231.
98. Thomas R.S., Clewell H.J., Allen B.C., Wesselkamper S.C., Wang N.C.Y., Lambert J.C., Hess-Wilson J.K., Zhao Q.J., Andersen M.E. Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol. Sci. 2011, 120:194-205.
99. Thompson M.R., Xu D., Williams B.R. ATF3 transcription factor and its emerging roles in immunity and cancer. J. Mol. Med. 2009, 87:1053-1060.
100. Tsuchishima M., George J., Shiroeda H., Arisawa T., Takegami T., Tsutsumi M. Chronic ingestion of ethanol induces hepatocellular carcinoma in mice without additional hepatic insult. Dig. Dis. Sci. 2013, 1-11.
101. Venables W.N., Ripley B.D. Modern Applied Statistics with S 1999, Springer-Verlag, New York. 3rd ed.
102. Wang J., Huang Q., Chen M. The role of NF-kappaB in hepatocellular carcinoma cell. Chin. Med. J. (Engl) 2003, 116:747-752.
103. Waters M.D., Jackson M., Lea I. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat. Res. Rev. Mutat. Res. 2010, 705:184-200.
104. Wu H., Kerr M., Cui X., Churchill G. MAANOVA: A software package for the analysis of spotted cDNA microarray experiments In the analysis of gene expression data 2003, (http://lectures.molgen.mpg.de/Genexpression_WS0506/material/wu2002.pdf).
105. Wu J., Li J., Salcedo R., Mivechi N.F., Trinchieri G., Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012, 72:3977-3986.
106. Yamada Y., Kirillova I., Peschon J.J., Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1441-1446.
107. Yang L., Allen B.C., Thomas R.S. BMDExpress: a software tool for the benchmark dose analyses of genomic data. BMC Genomics 2007, 8:387.
108. Young M.R., Yang H., Colburn N.H. Promising molecular targets for cancer prevention: AP-1, NF-κB and Pdcd4. Trends Mol. Med. 2003, 9:36-41.
109. Yuan L., Kaplowitz N. Glutathione in liver diseases and hepatotoxicity. Mol. Aspects Med. 2009, 30:29-41.
110. Yuan R., Jeng Y., Chen H., Lai P., Pan H., Hsieh F., Lin C., Lee P.H., Hsu H. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J. Pathol. 2006, 209:549-558.
111. Zhang Y., Chen F. Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res. 2004, 64:1902-1905.